Tech Mahindra Ltd (TECHM) Q1 FY27 Results Analysis: EBIT Margin Expands 379 bps, Deal Wins Stay Above $1Bn
CompoundingAI Research
Updated July 16, 2026
2 min read
Positive
Tech Mahindra Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 15,711.90 Cr (+17.68% YoY) and PAT growth of +28.45% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details| Results date | July 16, 2026 |
|---|
| Quarter | Q1 FY 2026-2027 |
|---|
| Revenue (Q1) | Rs. 15,711.90 Cr (+17.68% YoY) |
|---|
| PAT (Q1) | Rs. 1,465.10 Cr (+28.45% YoY) |
|---|
| EBITDA margin | 17.45% (+293 bps YoY) |
|---|
| EPS (Q1) | Rs. 16.53 (+28.44% YoY) |
|---|
| Market cap | Rs. 148,567.05 Cr |
|---|
| CMP | Rs. 1,515.85 |
|---|
Quarter Snapshot
USD revenue growth of 6.1% YoY is a clear acceleration from FY26's 1.9%, with EBIT margins expanding 379 bps YoY despite the Q1 salary cost cycle. Deal wins of $1,078 Mn (third consecutive $1Bn+ quarter) and all six verticals growing indicate broad-based demand. The 15% EBIT margin target for FY27 is on track, needing only ~60 bps further improvement over three quarters.
Key Investment Insights
Key Positives
- Revenue grew 17.7% YoY to Rs.15,711.9 Cr; USD revenue grew 6.1% YoY accelerating from FY26 full-year growth of 1.9%
- EBIT margin expanded 379 bps YoY to 14.41%, the highest Q1 level in at least three years
- Total Contract Value $1,078 Mn, third consecutive $1Bn+ quarter and +33% YoY
- Free Cash Flow $167 Mn, highest Q1 in available series, at 108% conversion of PAT
- Days Sales Outstanding improved to 84 days from 95 a year ago, the best in the available data series
- All six major verticals grew YoY; Europe geography standout at +8.1% QoQ and +12.1% YoY
Risk Factors
- Communications vertical (32.3% of revenue) declined 1.3% QoQ, remaining in low-growth mode
- Other expenses grew 13.1% QoQ and 26.7% YoY, outpacing revenue growth
- Effective tax rate increased to 27.21% from 24.25% in Q4 FY26, driven by a deferred tax charge of Rs.130.0 Cr
- Subsidiary contribution fell sharply to Rs.327.2 Cr from Rs.812.5 Cr in Q4 FY26 (though Q4 was inflated by a Rs.575.0 Cr impairment reversal effect in standalone)
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now